Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluorescence-guided meningioma surgery using Bevacizumab-IRDye800CW
NL-OMON25431Phase 2Recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Aug 2021
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of bevacizumab-IRDye800CW in meningioma (3 arms), sponsored by University Medical Center Groningen. Primary endpoints: Optimal dose of Bevacizumab-IRDye800CW in meningioma surgery and Safety of Bevacizumab-IRDye800CW administration. Started Aug 2021; status: recruiting.
02
Drugs
bevacizumab-IRDye800CW
03
Conditions
meningioma
Beyond the preview
Go deeper on NL-OMON25431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON25431.